-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head to Head Analysis: Celyad Oncology (NASDAQ:CYAD) Vs. Alterity Therapeutics (NASDAQ:ATHE)
Head to Head Analysis: Celyad Oncology (NASDAQ:CYAD) Vs. Alterity Therapeutics (NASDAQ:ATHE)
Alterity Therapeutics (NASDAQ:ATHE – Get Rating) and Celyad Oncology (NASDAQ:CYAD – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Institutional and Insider Ownership
3.2% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Celyad Oncology shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 0.9% of Celyad Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Get Alterity Therapeutics alerts:Earnings & Valuation
This table compares Alterity Therapeutics and Celyad Oncology's top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Alterity Therapeutics | $3.37 million | 3.89 | -$9.32 million | N/A | N/A |
Celyad Oncology | $10,000.00 | 4,045.87 | -$31.37 million | N/A | N/A |
Analyst Ratings
This is a breakdown of recent recommendations for Alterity Therapeutics and Celyad Oncology, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Alterity Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Celyad Oncology | 1 | 1 | 1 | 0 | 2.00 |
Alterity Therapeutics presently has a consensus target price of $2.50, suggesting a potential upside of 331.03%. Celyad Oncology has a consensus target price of $6.89, suggesting a potential upside of 284.70%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alterity Therapeutics is more favorable than Celyad Oncology.
Volatility & Risk
Alterity Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Celyad Oncology has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.
Profitability
This table compares Alterity Therapeutics and Celyad Oncology's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Alterity Therapeutics | N/A | N/A | N/A |
Celyad Oncology | N/A | N/A | N/A |
Summary
Alterity Therapeutics beats Celyad Oncology on 5 of the 8 factors compared between the two stocks.
About Alterity Therapeutics
(Get Rating)
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
About Celyad Oncology
(Get Rating)
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Alterity Treeutics(纳斯达克:Athe-Get Rating)和Celyad Oncology(纳斯达克:Cyad-Get Rating)都是小盘医疗公司,但哪一家是优势投资?我们将根据分析师推荐的实力、风险、机构所有权、盈利能力、收益、股息和估值对这两家公司进行比较。
机构和内部人持股
Alterity治疗公司3.2%的股份由机构投资者持有。相比之下,Celyad Oncology 29.1%的股份由机构投资者持有。Alterity治疗公司38.8%的股份由内部人士持有。相比之下,Celyad Oncology 0.9%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一只股票的长期表现将好于大盘。
到达交替治疗学警报:收益与估值
此表比较了Alterity Treateutics和Celyad Oncology的营收、每股收益和估值。
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
交替治疗学 | 337万美元 | 3.89 | -932万元 | 不适用 | 不适用 |
塞利亚德肿瘤学 | $10,000.00 | 4,045.87 | -3,137万元 | 不适用 | 不适用 |
分析师评级
这是由MarketBeat.com提供的Alterity治疗和Celyad肿瘤学最近建议的细目。
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
交替治疗学 | 0 | 1 | 1 | 0 | 2.50 |
塞利亚德肿瘤学 | 1 | 1 | 1 | 0 | 2.00 |
Alternity Treateutics目前的共识目标价为2.5美元,暗示潜在上涨331.03%。Celyad Oncology的共识目标价为6.89美元,暗示潜在上涨284.70。鉴于Alterity治疗公司更强的共识评级和更高的可能上行空间,股票研究分析师显然认为Alterity治疗公司比Celyad肿瘤学公司更有利。
波动性与风险
Alterity Treateutics的贝塔指数为1.23%,这表明其股价的波动性比S标准普尔500指数高23%。相比之下,Celyad Oncology的贝塔系数为1.28%,这表明其股价的波动性比S指数高28%。
盈利能力
此表比较了Alterity Treeutics和Celyad Oncology的净利润率、股本回报率和资产回报率。
净利润率 | 股本回报率 | 资产回报率 | |
交替治疗学 | 不适用 | 不适用 | 不适用 |
塞利亚德肿瘤学 | 不适用 | 不适用 | 不适用 |
摘要
与两只股票相比,Alternity Treateutics在8个因素中的5个方面击败了Celyad Oncology。
关于Alterity Treateutics
(获取评级)
Alternity Treateutics Limited在澳大利亚从事治疗阿尔茨海默病、亨廷顿病、帕金森病和其他神经疾病的治疗药物的研究和开发。该公司的主要候选药物是ATH434,它已经完成了治疗帕金森病的第一阶段临床试验。它还在开发PBT2,该产品已经完成了治疗阿尔茨海默病的IIa期临床试验。该公司前身为Prana Biotech Limited,于2019年4月更名为Alterity Treateutics Limited。另类治疗有限公司成立于1997年,总部设在澳大利亚墨尔本。
关于Celyad肿瘤学
(获取评级)
Celyad Oncology SA是一家临床阶段的生物制药公司,专注于发现和开发用于癌症治疗的嵌合抗原受体T(CAR-T)细胞疗法。它的主要候选产品包括用于治疗转移性结直肠癌的同种异体CAR-T候选药物Cyad-101,处于1b期临床试验的转移性结直肠癌;基于短发夹状RNA(ShRNA)的同种异体CAR-T候选药物,正处于治疗复发/难治性多发性骨髓瘤的第一阶段临床试验;以及正在进行第一阶段临床试验的自体CAR-T候选药物Cyad-02,用于治疗复发或难治性急性髓系白血病和骨髓增生异常综合征。该公司的临床前候选药物包括Cyad-203,一种非基因编辑的同种异体CAR-T候选药物,用于治疗实体肿瘤,与自然杀伤分子组2D配体(NKG2D)共表达细胞因子IL-18。它与诺华国际公司签署了与同种异体CAR-T细胞相关的美国专利的许可协议,并与Horizon Discovery Group plc进行了研发合作,并与Horizon Discovery Group plc签订了使用其shRNA技术生成第二个非基因编辑的同种异体平台的许可协议。该公司前身为Celyad SA,并于2020年6月更名为Celyad Oncology SA。Celyad Oncology SA成立于2004年,总部设在比利时圣吉伯特山。
接受Alterity治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Alterity Treateutics和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧